Note: This study is currently only recruiting patients in the hospital.

If you are interested in being notified if this study begins recruiting from the general population, please use the 'I Am Interested' button below.

Alopecia Areata Clinical Research Study

Seeking eligible participants with Alopecia Areata for a Phase II clinical study.

Brigham and Women's Hospital Hair Problems Immune System and Disorders Hair Loss
11 visits over 7 months
Estimated Time Commitment
Any Sex/Gender, 18-years or older
May Be Eligible
Payment up to $550
May Be Offered
Survey, Blood draw, Medication, Office visit
May Be Required
 
I Am Interested I Am Interested I Am Interested

This project is not recruiting.

Overview

What we are studying

The purpose of this study is to evaluate the safety, tolerability and efficacy of an investgational medicine in helping regrow hair in people with stable patchy alopecia areata.


Why it is important


What we hope to accomplish

Principal Investigator

Arash Mostaghimi, MD, MPA, MPH

Brigham and Women's Hospital

Public Profile

Who can participate


  • If you are equal to or greater than 18 years old.

  • Have a diagnosis of stable patchy alopecia areata with 15-95% hair loss on the scalp.

  • Individuals whose current hair loss episode has been a minimum of  6 months and a maximum of 12 years.

  • Individuals who are in good general health.

Who cannot participate


  • Individuals with other skin conditions on their scalp or another hair loss disorder such as androgenetic alopecia or scarring alopecia.

  • Individuals with significant medical conditions such as Cardiac, Renal, GI disease.


 

What you may be asked to do

Participation in the study will last approximately 7 months and include up to 11 vists to the study site. If you decide to take part, you might have to stop using your regular medication or therapy during the entire study.


The study doctor or study staff will give you study drug to put on your scalp. You will apply up to 4 mLs of the study drug 2 times a day (in the morning and evening approximately 12 hours apart) for 24 weeks.


You will be assigned by chance (like rolling a die) to 1 of the following study groups:
Group 1: ATI-50002 Topical Solution, 0.46%
Group 2: ATI-50002 Topical Solution, 0.12%
Group 3: Placebo Solution (a substance that looks like a drug, but has no drug in it)


You have an equal chance of being in any of the study groups. Neither you nor the study doctor or study staff will be able to pick which study group you are in. You will not know and the study doctor or study staff will not know which study group you are in. The study doctor or study staff can find out if it is necessary to know for your health. If this happens, the study doctor or study staff may not be able to tell you which study group you were in until everyone finishes the study.


The investigational study medication and study-related tests/evaluations will be provided at no cost.


 


Project activities may include:

  • Survey
  • Blood draw
  • Medication
  • Office visit

Estimated Time Commitment

11 visits over 7 months

What You May Get

For your time and inconvenience related to your participation in this study, you will be paid up to a total of $550.00 if you complete the study. If you do not complete the study, for any reason, you will be paid for the study visits you do complete according to the following schedule, $50.00 for each visit.

Location


221 Longwood Avenue, Boston

Map it!


Travel

  • Accessible by public transportation
  • Local travel reimbursed
  • Parking available
  • Parking reimbursed
  • Travel reimbursed
  • Out of state travel possibly reimbursed

Travel and Parking Details

Additional Information

ClinicalTrials.gov Identifier

NCT03354637


Study Phase

Phase 2: This project studies whether a medication or treatment works for people with a specific disease or condition. The drug or treatment has been studied for safety in healthy volunteers, but the project will continue to look at safety and short term side effects.


Participating Institutions


Funding Source

  • Industry
Top